Alexion Pharmaceuticals Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/10/2021)
| Balance Sheet | Total Assets | 18,103,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 11,651,200,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -106,700,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 2,896,200,000.00 | – | – |
| Cashflow | Operating Cash Flow | 3,002,900,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.72 | Div. Yield | – |
| Income | Net Income | 603,400,000.00 | P/E | – |
| Income | Shares Outstanding | 444,000,000.00 | P/B | – |
| Income | Total Revenue | 6,069,900,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.alexion.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more